Open Orphan #ORPH – Journal for Clinical Studies article publication
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces that an article has been written and published in the Journal for Clinical Studies (“JCS”). The article, entitled “Hot Topics – Vaccine Solutions for Tropical Diseases” is written […]
Open Orphan #ORPH – Ethics approval – COVID-19 Human Challenge Study
Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces the world’s first COVID-19 characterisation study has received approval from a specially convened Research Ethics Committee (“REC”). This news follows the announcement on 20 October 2020 […]
Open Orphan #ORPH – Exercise of Investor Warrants by Investors, Issue of Shares and TVR
Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organization (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials , has received notice of exercise of warrants by investors who participated in the Venn loan note financing in December 2018 over 1,349,349 ordinary shares of 0.1 pence each in […]
Open Orphan #ORPH – New challenge study quarantine clinic at Whitechapel
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services contract research organization (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces that hVIVO, part of Open Orphan plc, has opened a new quarantine clinic in East London. The new site is based in Whitechapel, directly opposite the […]
Bidstats confirmation of hVIVO contract award as announced by Open Orphan #ORPH in October 2020
Bidstats, the website that displays HM Govt procurement notices, tenders and awards, and contract information is now displaying the £46m contract award to Open Orphan #ORPH subsidiary hVIVO.
Open Orphan #ORPH – Article Published in Drug Discovery Today
Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organization (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces an article submission has been published in Drug Discovery Today, a print and online trade magazine with an emphasis on the science which underpins drug discovery […]
Open Orphan #ORPH – Expansion of volunteer recruitment centres for human challenge trials
Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and the world leader in vaccine and antiviral testing using human challenge clinical trials, has opened two new volunteer recruitment centres to screen potential trial volunteers, the first in East London and a second in central Manchester. These new locations are […]
Open Orphan #ORPH – First volunteer dosed in intranasal COVID-19 vaccine clinical trial
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces that the first volunteer has been dosed with the Codagenix Inc. (“Codagenix”) needle free, intranasal COVID-19 vaccine, COVI-VAC. Conducted by hVIVO, part of Open Orphan plc, the Phase I […]
Daily Mail – The volunteers who are DELIBERATELY catching Covid: 2,500 Britons will take part in the world’s first ‘human challenge trials’ run by Imperial College next month in bid to accelerate research on pandemic
by Faith Ridler The volunteers who are DELIBERATELY catching Covid: 2,500 Britons will take part in the world’s first ‘human challenge trials’ run by Imperial College next month in bid to accelerate research on pandemic Alex Greer, 20, will take part in the human challenge trials in London next month Those in the study will […]
Open Orphan #ORPH – Successful completion of PrEP Biopharm Toxicology study for respiratory ‘viral mimic’
Phase IIb study to validate efficacy of PrEP-001 against circulating respiratory viruses such as COVID-19, flu and the common cold Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials, announces that drug development company PrEP Biopharm […]